Outcomes of persistent pulmonary hypertension following transcatheter aortic valve replacement.
Ahmad MasriIslam AbdelkarimMichael S SharbaughAndrew D AlthouseJeffrey XuWei HanStephen Y ChanWilliam E KatzFrederick W CrockMatthew E HarinsteinDustin E KlinerForozan NavidJoon S LeeThomas G GleasonJohn T SchindlerJoão L CavalcantePublished in: Heart (British Cardiac Society) (2017)
Persistency of even moderate or greater PH at 1 month post-TAVR is common and associated with higher all-cause mortality.